Investors holding ADSs through brokers will receive ordinary shares automatically; no action is required. Traders should anticipate potential short-term volatility around the transition date due to changes in trading mechanics and investor base adjustments.
Price Chart
Executive Summary
Ascendis Pharma A/S announced a transition to a direct listing of its ordinary shares on Nasdaq, replacing its American Depositary Shares (ADSs). Each ADS will be mandatorily exchanged for one ordinary share, with trading of ordinary shares set to begin on April 20, 2026, under the existing ticker ASND. The last day of ADS trading is expected to be April 17, 2026.
Key Facts
- Ascendis Pharma is transitioning from ADSs to direct listing of ordinary shares on Nasdaq.
- The exchange of ADSs for ordinary shares will occur on a 1:1 basis.
- Trading of ordinary shares is expected to commence on April 20, 2026.
- The last day of ADS trading is expected to be April 17, 2026.
- The Bank of New York Mellon will manage the mandatory exchange process.
Financial Impact
No change in underlying equity value; this is a structural change from ADSs to ordinary shares with no dilution or capital raise.
Risk Factors
- Risk that the exchange process encounters delays or operational issues.
- Potential for reduced liquidity or altered trading dynamics post-transition.
- Possible adverse tax implications for certain ADS holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-147597 |
| Document: 0001193125-26-147597-index-headers.html | 0001193125-26-147597 |
| Document: 0001193125-26-147597-index.html | 0001193125-26-147597 |
| Document: 0001193125-26-147597.txt | 0001193125-26-147597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access